{"id":"placebo-to-telmisartan","safety":{"commonSideEffects":[{"rate":"7-10","effect":"Dizziness"},{"rate":"7","effect":"Upper respiratory tract infection"},{"rate":"3","effect":"Back pain"},{"rate":"3","effect":"Pharyngitis"},{"rate":"1-2","effect":"Hyperkalemia"},{"rate":"1-2","effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL1017","moleculeType":"Small molecule","molecularWeight":"514.63"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Telmisartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors on vascular smooth muscle and other tissues. By blocking angiotensin II signaling, it causes vasodilation and reduces aldosterone secretion, leading to decreased blood pressure and reduced cardiac workload. This mechanism also provides renal protection and cardiovascular benefits beyond blood pressure reduction.","oneSentence":"Telmisartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:27.885Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Cardiovascular risk reduction in patients with hypertension"}]},"trialDetails":[{"nctId":"NCT07207057","phase":"PHASE3","title":"Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial","status":"RECRUITING","sponsor":"University College, London","startDate":"2025-09-12","conditions":"Parkinsons Disease (PD)","enrollment":1200},{"nctId":"NCT06647745","phase":"PHASE3","title":"A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension","status":"RECRUITING","sponsor":"THPharm Corp.","startDate":"2025-04-10","conditions":"Type 2 Diabetes, Hypertension","enrollment":221},{"nctId":"NCT04518306","phase":"PHASE3","title":"Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension","status":"COMPLETED","sponsor":"George Medicines PTY Limited","startDate":"2021-06-14","conditions":"Hypertension","enrollment":755},{"nctId":"NCT00274105","phase":"PHASE4","title":"SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2001-03-01","conditions":"Hypertension, Coronary Arteriosclerosis","enrollment":22},{"nctId":"NCT02620163","phase":"PHASE3","title":"Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2015-12","conditions":"Hypertension","enrollment":381},{"nctId":"NCT02471833","phase":"PHASE1, PHASE2","title":"Health Evaluation in African Americans Using RAS Therapy","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-04","conditions":"Alzheimer's Disease","enrollment":61},{"nctId":"NCT04970108","phase":"PHASE3","title":"Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and Hypertension","status":"WITHDRAWN","sponsor":"EMS","startDate":"2023-08","conditions":"Hypertension Associated, Type II Diabetes Mellitus","enrollment":""},{"nctId":"NCT05144360","phase":"PHASE3","title":"Efficacy and Safety of Atenas Association in the Treatment of Type II Diabetes Mellitus and Hypertension","status":"WITHDRAWN","sponsor":"EMS","startDate":"2022-08","conditions":"Hypertension Associated, Type II Diabetes Mellitus","enrollment":""},{"nctId":"NCT04021550","phase":"EARLY_PHASE1","title":"Improving 24-hour Blood Pressure in Obstructive Sleep Apnea","status":"WITHDRAWN","sponsor":"University of British Columbia","startDate":"2023-05","conditions":"Obstructive Sleep Apnea","enrollment":""},{"nctId":"NCT02593110","phase":"NA","title":"Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2016-01-04","conditions":"Peripheral Artery Disease","enrollment":114},{"nctId":"NCT04394117","phase":"PHASE4","title":"Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease","status":"COMPLETED","sponsor":"The George Institute","startDate":"2020-06-19","conditions":"Coronavirus Disease 2019, COVID-19","enrollment":787},{"nctId":"NCT04218552","phase":"PHASE2","title":"Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2020-02-25","conditions":"Hypertension,Essential","enrollment":176},{"nctId":"NCT04436419","phase":"NA","title":"Immunometabolic Effects of Non-drug Strategies in the Clinical Management of Obesity: Translational Study","status":"COMPLETED","sponsor":"Fauqué","startDate":"2018-07-02","conditions":"Obesity, Obesity, Abdominal, Obesity, Visceral","enrollment":40},{"nctId":"NCT01885559","phase":"PHASE3","title":"HALT Progression of Polycystic Kidney Disease Study B","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2006-01","conditions":"Kidney, Polycystic","enrollment":486},{"nctId":"NCT00283686","phase":"PHASE3","title":"HALT Progression of Polycystic Kidney Disease Study A","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2006-01","conditions":"Kidney, Polycystic","enrollment":558},{"nctId":"NCT01202721","phase":"PHASE3","title":"Beta Blockers and Angiotensin Receptor Blockers in Bicuspid Aortic Valve Disease Aortopathy (BAV Study)","status":"TERMINATED","sponsor":"Hamilton Health Sciences Corporation","startDate":"2011-06","conditions":"Cardiac Disease","enrollment":85},{"nctId":"NCT03088254","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin","status":"COMPLETED","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2016-09-20","conditions":"Dyslipidemia With Hypertension","enrollment":126},{"nctId":"NCT03566316","phase":"PHASE3","title":"Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2015-11-24","conditions":"Hypertension With Hyperlipidemia","enrollment":134},{"nctId":"NCT00281593","phase":"PHASE3","title":"Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-04","conditions":"Hypertension","enrollment":1354},{"nctId":"NCT02734355","phase":"PHASE4","title":"Left Atrial Mechanical Function Improvement After Atrial Fibrillation Catheter Ablation","status":"COMPLETED","sponsor":"Research Institute for Complex Problems of Cardiovascular Diseases, Russia","startDate":"2015-11","conditions":"Atrial Fibrillation","enrollment":64},{"nctId":"NCT00147264","phase":"PHASE3","title":"Telmisartan-Induced Reduction in Intra-Myocellular Lipids Trial","status":"COMPLETED","sponsor":"McMaster University","startDate":"2004-04","conditions":"Metabolic Syndrome X","enrollment":120},{"nctId":"NCT01975246","phase":"PHASE3","title":"Add-on to Micamlo BP Trial","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-11","conditions":"Hypertension","enrollment":309},{"nctId":"NCT02738632","phase":"PHASE3","title":"Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2015-05","conditions":"Essential Hypertension","enrollment":300},{"nctId":"NCT01377285","phase":"PHASE4","title":"Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD)","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2010-06","conditions":"Chronic Renal Failure","enrollment":350},{"nctId":"NCT01911780","phase":"PHASE3","title":"Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-07","conditions":"Hypertension","enrollment":132},{"nctId":"NCT02264158","phase":"PHASE1","title":"Influence of Telmisartan and Lacidipine, Combined or Alone, on QT Interval in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-09","conditions":"Healthy","enrollment":149},{"nctId":"NCT02261116","phase":"PHASE4","title":"Study to Assess Potential Different Properties of Telmisartan Compared to Candesartan in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-04","conditions":"Healthy","enrollment":24},{"nctId":"NCT02260089","phase":"PHASE4","title":"Telmisartan in Mild to Moderate Hypertensive Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-03","conditions":"Hypertension","enrollment":134},{"nctId":"NCT02242812","phase":"PHASE4","title":"Telmisartan Effectiveness on Left Ventricular Mass Reduction (TELMAR) as Assessed by MRI, in Patients With Mild to Moderate Hypertension","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2003-09","conditions":"Hypertension","enrollment":24},{"nctId":"NCT02242318","phase":"PHASE4","title":"Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-09","conditions":"Hypertension","enrollment":440},{"nctId":"NCT02206659","phase":"PHASE3","title":"Effects of Telmisartan by Ambulatory Blood Pressure Monitoring (ABPM) in Chinese Patients With Mild to Moderate Essential Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-08","conditions":"Hypertension","enrollment":20},{"nctId":"NCT02200653","phase":"PHASE4","title":"A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® / LORZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-05","conditions":"Hypertension","enrollment":387},{"nctId":"NCT02200640","phase":"PHASE4","title":"A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-03","conditions":"Hypertension","enrollment":333},{"nctId":"NCT02187536","phase":"PHASE1","title":"Pharmacokinetics of Simvastatin and Its Metabolite Simvastatin Acid With and Without Concomitant Administration of Telmisartan in Healthy Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-04","conditions":"Healthy","enrollment":16},{"nctId":"NCT02176499","phase":"PHASE3","title":"Natriuretic Effect of Telmisartan Versus Placebo in Patients With Mild-to-Moderate Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1999-02","conditions":"Hypertension","enrollment":26},{"nctId":"NCT02177396","phase":"PHASE3","title":"MICARDIS® and Valsartan in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-04","conditions":"Hypertension","enrollment":426},{"nctId":"NCT01914432","phase":"PHASE3","title":"Efficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2013-11","conditions":"Hyperlipidemia, Hypertension","enrollment":210},{"nctId":"NCT02177435","phase":"PHASE3","title":"Telmisartan With or Without Hydrochlorothiazide in Patients With Mild-to-moderate Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1999-02","conditions":"Hypertension","enrollment":491},{"nctId":"NCT02177500","phase":"PHASE3","title":"Telmisartan Plus Hydrochlorothiazide in Subjects With Mild-to-moderate Hypertension Who Failed to Respond to Telmisartan Monotherapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-01","conditions":"Hypertension","enrollment":327},{"nctId":"NCT02183701","phase":"PHASE3","title":"Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-04","conditions":"Hypertension","enrollment":715},{"nctId":"NCT02177409","phase":"PHASE3","title":"Telmisartan Versus Amlodipine in Patients With Mild-to-Moderate Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-04","conditions":"Hypertension","enrollment":431},{"nctId":"NCT02178306","phase":"PHASE4","title":"Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-09","conditions":"Hypertension","enrollment":82},{"nctId":"NCT01204398","phase":"PHASE3","title":"Telmisartan+Amlodipine Fixed Dose Combination in Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-11","conditions":"Hypertension","enrollment":27},{"nctId":"NCT00153101","phase":"PHASE4","title":"Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-11","conditions":"Cardiovascular Diseases","enrollment":31546},{"nctId":"NCT00281580","phase":"PHASE3","title":"Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-04","conditions":"Hypertension","enrollment":1461},{"nctId":"NCT02087540","phase":"PHASE3","title":"Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia","status":"UNKNOWN","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2013-05","conditions":"Hypertension, Hyperlipidemia","enrollment":310},{"nctId":"NCT01983735","phase":"PHASE3","title":"Efficacy and Safety of TELMINUVO to Stage 2 Hypertension","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2014-01","conditions":"Hypertension","enrollment":200},{"nctId":"NCT00153088","phase":"PHASE4","title":"INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-01","conditions":"Diabetic Nephropathies","enrollment":527},{"nctId":"NCT00146289","phase":"PHASE2","title":"The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-02","conditions":"Obesity, Insulin Resistance","enrollment":138},{"nctId":"NCT01634295","phase":"PHASE3","title":"Efficacy and Safety of CKD-828 to Stage 2 Hypertension","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2012-07","conditions":"Hypertension","enrollment":103},{"nctId":"NCT00562952","phase":"PHASE2, PHASE3","title":"Nt-proBNP Guided Primary Prevention of CV Events in Diabetic Patients","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2007-11","conditions":"Diabetes Mellitus, Heart Failure, Coronary Artery Disease","enrollment":300},{"nctId":"NCT00865020","phase":"PHASE4","title":"Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-03","conditions":"Hypertension","enrollment":822},{"nctId":"NCT01128322","phase":"PHASE2","title":"CKD-828 Primary Hypertension Trial(Dose-selection)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2010-07","conditions":"Hypertension","enrollment":430},{"nctId":"NCT00490958","phase":"PHASE4","title":"Telmisartan in Haemodialysis Patients With Chronic Heart Failure","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"1999-01","conditions":"Heart Failure, Congestive","enrollment":351}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":251,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo to Telmisartan","genericName":"Placebo to Telmisartan","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Telmisartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure. Used for Hypertension, Cardiovascular risk reduction in patients with hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}